The estimated Net Worth of Gary Gelman is at least $8.55 Миллион dollars as of 3 January 2012. Gary Gelman owns over 1,000,000 units of Aileron Therapeutics Inc stock worth over $8,341,632 and over the last 20 years Gary sold ALRN stock worth over $213,150.
Gary has made over 5 trades of the Aileron Therapeutics Inc stock since 2004, according to the Form 4 filled with the SEC. Most recently Gary bought 1,000,000 units of ALRN stock worth $2,000,000 on 3 January 2012.
The largest trade Gary's ever made was buying 1,000,000 units of Aileron Therapeutics Inc stock on 3 January 2012 worth over $2,000,000. On average, Gary trades about 175,000 units every 433 days since 2004. As of 3 January 2012 Gary still owns at least 2,896,400 units of Aileron Therapeutics Inc stock.
You can see the complete history of Gary Gelman stock trades at the bottom of the page.
Gary's mailing address filed with the SEC is , ONE JERICHO PLAZA, JERICHO, NY, 11753.
Over the last 14 years, insiders at Aileron Therapeutics Inc have traded over $6,473,296 worth of Aileron Therapeutics Inc stock and bought 16,658,005 units worth $51,661,886 . The most active insiders traders include Muneer A Satter, Bioventures Ltd Novartis Ag... и Armen Shanafelt. On average, Aileron Therapeutics Inc executives and independent directors trade stock every 77 days with the average trade being worth of $908,853. The most recent stock trade was executed by Of Texas/Texas Am Investmen... on 14 June 2024, trading 6,607 units of ALRN stock currently worth $21,539.
aileron is the clinical-stage leader in the field of stapled peptide therapeutics for cancers and other diseases. our lead product candidate, alrn-6924, which is being evaluated in multiple clinical trials, reactivates p53-mediated tumor suppression by targeting both of the primary p53 suppressor proteins mdmx and mdm2. the p53 protein, often referred to as the “guardian of the genome,” is known for its central role in preventing cancer initiation and progression, and its inactivation is essential for the formation of virtually all cancers. we believe that alrn-6924 is the first and only product candidate in clinical development that can inhibit both mdmx and mdm2, which we believe, based on published data and our preliminary clinical results, are equally important in restoring p53 function as the body’s first line of defense against cancer. based on preclinical data and preliminary evidence of safety and anti-tumor activity in our ongoing clinical trials, we believe there may be a sig
Aileron Therapeutics Inc executives and other stock owners filed with the SEC include: